White Paper

KRAS Biomarker Becomes a Target of Choice in Certain Cancer Therapies

Download  White Paper

Get the latest insights on KRAS and see how it has switched from being an undruggable to a druggable cancer target

In this white paper, find out more about:

  • The structure and function of the RAS protein superfamily
  • The role and consequences of KRAS gene activation
  • How renowned companies are targeting KRAS in cancer therapies and what the current challenges in developing KRAS-targeted therapeutics are
  • How to identify novel KRAS inhibitors and how to characterize downstream KRAS signaling with Alpha Surefire® Ultra and HTRF® technologies

Download  White Paper

PerkinElmer and Cisbio logo